SymBio Pharmaceuticals Ltd. Sponsored ADR (SYMQY)

Overview

SymBio Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of novel treatments in the fields of oncology and hematology. Established in 2005 and headquartered in Tokyo, Japan, the company operates on a global scale. It is dedicated to advancing healthcare solutions through the research and development, manufacturing, and marketing of pharmaceutical drugs. Its commitment to improving patient outcomes is evident in its portfolio of marketed drugs and those in development, catering specifically to critical areas such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, myelodysplastic syndromes, and antiviral treatments.

Products and Services

• SyB L-0501 - An anti-cancer agent, marketed under the TREAKISYM brand, for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma. The drug has garnered attention for its effectiveness in these hard-to-treat conditions.
• SyB L-1701 - A ready-to-dilute formulation that represents SymBio’s commitment to improving the administration and handling of oncology treatments, aiming to enhance patient convenience and safety during treatment.
• SyB L-1702 - A rapid infusion liquid administrator also under the TREAKISYM name, developed to streamline the treatment process for patients and healthcare providers, ensuring a more efficient delivery of care.
• SyB L-1101 - An intravenous formulation targeting higher-risk myelodysplastic syndromes (HR-MDS). Having completed Phase III clinical trials, it is a promising candidate for addressing the needs of patients with this challenging condition.
• SyB C-1101 - An oral formulation currently in Phase I/II clinical trial, in combination with AZA, for the treatment of HR-MDS. This development represents an innovative approach to treatment, offering hope for more accessible and less invasive options for patients.
• SyB V-1901 - An antiviral drug in development, showcasing SymBio’s expansion into the infectious disease arena. This underlines the company's versatility and commitment to addressing a broad spectrum of human diseases.